Ann: Medibio Quarterly Update and Cashflow Report, page-23

some good snippets

"The overall percent agreement was 84.70%, which resulted in significantly greater accuracy than the overall percentage agreement of the chosen predicate device (73%)"

"Importantly, the speed (1-2 minute analysis by MEBsleep vs 60-90 minutes by a technician), accuracy and the AI characteristics of MEBsleep offers significant advantages over other sleep staging software in the market. Medibio is now planning for commercial opportunities in the USA in anticipation of FDA clearance, expected in August 2020. Furthermore, the Company will shortly be submitting MEBsleep for CE Mark approval, which will allow commercialisation in Europe."

"Discussions regarding the re-sale and implementation of ilumen™ both in Australia and internationally are well advanced with Compass Group PLC in London; and separately with its Australian subsidiary, following the successful completion of a number of paid pilot programs"

"Discussions are also on-going with DXC regarding a Re-seller Agreement, whereby DXC will promote ilumenTM to its substantial client base. "